Abzena Group

Website:
www.abzena.com
Organisation type
Dr Donna Hackett
VP Intellectual Property, Commercial and Legal Affairs 
Mr John Burt
CEO 
Dr George Badescu
Director, Scientific Affairs 

BioIndustry Association

The UK BioIndustry Association, the BIA, is the trade association for innovative enterprises involved in UK bioscience. Members include start-up, emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA works to further the interests of members and the industry – nationally and internationally. Our heritage of innovation, enterprise and success dates back to our founding over 20 years ago

Membership affiliation
Organisation type
Mr Steve Bates
CEO 

CLINICAL ACCELERATOR

Clinical Accelerator conducts all phases of clinical trials for pharma, biotech and medtech companies.
Keywords
clinical trials,study design
Membership affiliation
Organisation type
Dr NIKOLAI NIKITIN
DIRECTOR 

Clinical Network Services (UK) Ltd

Clinical Network Services (CNS) is an Australian, New Zealand and UK based service group, offering full and integrated drug development consultancy to small – medium sized Biotech companies from inception through to end of phase II clinical trial programs. CNS offers a unique service that brings together BioDesk; an intelligent product development and regulatory planning service, with our highly experienced regional clinical operations and data management teams.

BioDesk is a team of in-house scientists and commercial drug development experts, who work closely with our clients from the earliest of planning stages. Together they create and manage Drug Development Plans, including all stages of pre-clinical/CMC programs that embrace global regulatory strategies whilst leveraging our unique regional advantage.

Australia and New Zealand have an outstanding product development timeline advantage due to our access to a pragmatic regulatory environment that makes it possible to add value to the global regulatory dossier and enter the clinic quickly, without the need for prior approval from another regulatory agency. Our clients have often established initial proof-of-concept quickly, and have enjoyed a time(cost) saving when compared to the more resource-intensive strategy of applying for an IND or CTA.

CNS has worked with clients whose cumulative acquisition price exceeds US$16.5billion; many of these clients initially fast-tracked their programs by running their phase 1 & 2 studies in Australia and New Zealand.

Keywords
product development,regulatory,consultancy
Membership affiliation
Organisation type
Mr Russell Neal
Managing Director 
Ms Megan Hill
Business Development Manager 

Domainex Ltd

Domainex is a drug discovery company with a reputation for speed and innovation built on an exceptional track record of drug candidate delivery. It has a world class discovery team with an unrivalled track record and three client drug candidates.

Membership affiliation
Organisation type
Dr Edward Littler
CEO 

Sentinext

Membership affiliation
Organisation type
Mr David Lawrence
CEO